
Results 1 - 20 of 37 in Foradil, Formoterol (generic)
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of...
Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 2a dose-ranging study of PT001, the company's glycopyrrolate hydrofluoroalkane metered dose inhaler formulation. Comment?
Pearl Therapeutics Announces Positive Results From Phase 2a Trial of...
Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from its first clinical trial in patients with chronic obstructive pulmonary disease . Comment?
Pearl Therapeutics Announces Positive Results From Phase 2a...
Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from its first clinical trial in patients with chronic obstructive pulmonary disease . Comment?
Asthma medications can fall into three general categories: relievers, controllers, and combination medications. Comment?
Defective macrophage phagocytosis of bacteria in COPD.
HEIRS Immunology and Autoimmune Diseases's tags for this article Abstract Exacerbations of chronic obstructive pulmonary disease are an increasing cause of hospitalizations and are associated with accelerated progression of airflow obstruction. Comment?
Heart Disease Home > Questions > Sever pain left side just above the rib cage bottom and a little toward the front. Comment?
WADA list of prohibited substances 2010
The World Anti-Doping Agency has issued a new list of prohibited substances for 2010 and a new International Standards for Therapeutic Use Exemption , which will come into effect on 1 January 2010. Comment?
SkyePharma: flutiform Phase III study complete
SkyePharma Plc, /quotes/comstock/11i!skyef /quotes/comstock/23s!e:skp the London producer of pharmaceuticals using proprietary drug-delivery technologies, said that a partner, Mundipharma International Corp., completed the final Phase III study of flutiform, which is being developed to treat asthma. Comment?
Flutiform EU Clinical Trial Successfully Completed
FOR IMMEDIATE RELEASE SkyePharma Announces Successful Completion of FlutiformTM EU Clinical Trial Programme LONDON, UK, 2 November, 2009 - SkyePharma PLC today announces that its development and marketing partner Mundipharma International Corporation Limited has successfully completed the final Phase III clinical study for the European development ... Comment?
Chronic obstructive pulmonary disease is a leading cause of death and disability in the United States. Comment?
Inhaled Steroids: More Harm Than Good in COPD?
In people who suffer from COPD, a progressive lung disease that makes it hard to breathe, adding an inhaled steroid to a so-called "long-acting beta-2 agonist" may do more harm than good, new research hints. Comment?
Triple Therapy Beneficial in Chronic Pulmonary Disease
w/Photo
In patients with chronic obstructive pulmonary disease , triple therapy with budesonide/formoterol added to tiotropium significantly improves lung function and reduces severe exacerbations compared to monotherapy with tiotropium, according to a study published in the Oct. Comment?
Inhaled steroids: more harm than good in COPD?
In people who suffer from COPD, a progressive lung disease that makes it hard to breathe, adding an inhaled steroid to a so-called "long-acting beta-2 agonist" may do more harm than good, new research hints. Comment?
Triple Therapy Halves Exacerbations In Moderate-to-Severe COPD
Main Category: COPD Also Included In: Respiratory / Asthma Article Date: 08 Oct 2009 - 19:00 PDT Patients with moderate to severe chronic obstructive pulmonary disease can benefit from triple therapy that includes a long-acting I2-agonist , an inhaled corticosteroid and an anti-muscarinic agent, according to researchers in Germany. Comment?
Triple Therapy Halves Exacerbations In Moderate-to-Severe COPD
Patients with moderate to severe chronic obstructive pulmonary disease can benefit from triple therapy that includes a long-acting I2-agonist , an inhaled corticosteroid and an anti-muscarinic agent, according to researchers in Germany. Comment?
Triple Therapy Halves Exacerbations In Moderate-To-Severe COPD
Patients with moderate to severe chronic obstructive pulmonary disease can benefit from triple therapy that includes a long-acting I2-agonist , an inhaled corticosteroid and an anti-muscarinic agent, according to researchers in Germany. Comment?
Kylie is Bowled over by US tour
w/Photo
COUGHING violently and struggling for breath, Julie Underwood was finally forced to admit defeat. Comment?
Developing robust formoterol-containing suspension pMDIs with enhanced shelf lives
Formoterol is increasingly viewed as the long-acting I22-agonist of choice by pharmaceutical companies wishing to participate in the dynamic inhaled corticosteroid plus long-acting I22-agonist combination therapy segment of the asthma and chronic obstructive pulmonary disease market. Comment?
Symbicort(R) Turbuhaler(R) SMART Improves Asthma Symptom Control And...
European Respiratory Society Congress 2009, Vienna, Austria, 15 September 2009: Symbicort Turbuhaler Maintenance and Reliever Therapy provides effective symptom control and reduces the risk of severe exacerbations in symptomatic asthma patients on inhaled corticosteroids or combination therapy of ICS and long-acting beta agonists over six months ... Comment?
SkyePharma Inc. Says More Tests Needed for Asthma Drug
As previously announced, in June 2009 the FDA gave preliminary notice of some potential review issues which it had identified in its preliminary evaluation of the NDA, which had been accepted for substantive review. Comment?